Scancell's Rise is Dendreon's Doom! - 500 Beiträge pro Seite
eröffnet am 13.02.13 09:09:23 von
neuester Beitrag 22.01.15 09:51:31 von
neuester Beitrag 22.01.15 09:51:31 von
Beiträge: 43
ID: 1.179.463
ID: 1.179.463
Aufrufe heute: 0
Gesamt: 3.996
Gesamt: 3.996
Aktive User: 0
ISIN: GB00B63D3314 · WKN: A1JZ3D · Symbol: SCP
0,0765
EUR
-16,85 %
-0,0155 EUR
Letzter Kurs 08:10:51 Frankfurt
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 1,6800 | +37,14 | |
| 2,4700 | +33,51 | |
| 3,4600 | +17,69 | |
| 0,6889 | +16,78 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8501 | -17,47 | |
| 1,3017 | -18,64 | |
| 5,3100 | -18,81 | |
| 5,0550 | -22,71 | |
| 0,6021 | -35,26 |
Feedback
SCANCELL'S RISE IS DENDREON'S DOOM!
The Dendreon Corporation is the one and only global leader in therapeutic cancer vaccines. The technology they use requires extracting immune system alarm cells (dendritic cells) from the patient's blood, pulsing them with cancer antigens and injecting them back into that same patient. This has proved prohibitively expensive. Scancell therefore designed an alternative solution and has provided the industry and the regulatory authorities with a more commercially viable product: a DNA dendtritic cell vaccine which coats the alarm cells with epitopes of cancer antigens while those alarm cells are still in the patient's body. This provides a solution with no rejection problems and can therefore be given to any number of patients without having to manufacture a fresh batch.
Dendreon's Provenge, to treat prostate cancer, is the first and only therapeutic cancer vaccine commercially approved to date but the business model behind it is fatally flawed and the industry knows it. The treatment is simply unaffordable. So as Dendreon's stock has plummeted, Scancell's stock has risen, making Scancell London's best performing stock of 2012. Without doubt Scancell remains the most significant ongoing threat to Dendreon's dominance.
Research link:
http://www.scancell.co.uk/Apps/Content/html/?fid=6
The Dendreon Corporation is the one and only global leader in therapeutic cancer vaccines. The technology they use requires extracting immune system alarm cells (dendritic cells) from the patient's blood, pulsing them with cancer antigens and injecting them back into that same patient. This has proved prohibitively expensive. Scancell therefore designed an alternative solution and has provided the industry and the regulatory authorities with a more commercially viable product: a DNA dendtritic cell vaccine which coats the alarm cells with epitopes of cancer antigens while those alarm cells are still in the patient's body. This provides a solution with no rejection problems and can therefore be given to any number of patients without having to manufacture a fresh batch.
Dendreon's Provenge, to treat prostate cancer, is the first and only therapeutic cancer vaccine commercially approved to date but the business model behind it is fatally flawed and the industry knows it. The treatment is simply unaffordable. So as Dendreon's stock has plummeted, Scancell's stock has risen, making Scancell London's best performing stock of 2012. Without doubt Scancell remains the most significant ongoing threat to Dendreon's dominance.
Research link:
http://www.scancell.co.uk/Apps/Content/html/?fid=6
Antwort auf Beitrag Nr.: 44.134.271 von IronSioux am 13.02.13 09:09:23wenn ich das richtig überflogen habe, sind die in Phase 1/2 der Studien, d.h. wenns gut geht vielleicht 2016/2017 Markteinführung. Knapp 200 Mio Aktien zu ca. 0,44 € macht 80 Mio € Bewertung. Das vorhandene Geld wird wohl Ende 2013 zur Neige gehen, damit kommt eine signifikante weitere Verwässerung... kann interessant werden, reißt mich aber im Moment nicht von Hocker.
Da ist evtl MOLOGEN etwas besser geeignet. Die habe auch eine immunisierte Tumortherapie mit MGN1601, allerdings anderer technologischer Background http://www.mologen.com/de/produkte/onkologie/mgn1601.html.
Spannender ist aber deren MGN1703, wo zeitnah der Deal mit BigPharma erwartet wird... Der Kurs der Aktie ist schon gut gelaufen, dennoch m.E. Verdopplung des Kurses bis Ende 2013 gut möglich....
Da ist evtl MOLOGEN etwas besser geeignet. Die habe auch eine immunisierte Tumortherapie mit MGN1601, allerdings anderer technologischer Background http://www.mologen.com/de/produkte/onkologie/mgn1601.html.
Spannender ist aber deren MGN1703, wo zeitnah der Deal mit BigPharma erwartet wird... Der Kurs der Aktie ist schon gut gelaufen, dennoch m.E. Verdopplung des Kurses bis Ende 2013 gut möglich....
NEW CANCER VACCINES IN WEEKS!
Scancell is a great investment opportunity. The company makes unique reprogrammable vaccines to fight cancer. That's right, reprogrammable!
Scancell's vaccines are based on small pieces of DNA that program a patient's dendritic cells to make mimics of certain chemicals found in the particular cancer that the patient is suffering from. These chemical markers are then shown to the immune system's Killer T Cells which use them, like a bloodhound, to sniff out cancer and destroy it.
Scancell's technology is called ImmunoBody and the first vaccine of this type, code named SCIB1, is designed to treat skin cancer. This vaccine is intended to be a 'showcase vaccine' to display the ability of ImmunoBody to combat the disease.
Because some cancers display different chemical markers, new vaccines need to be designed to help the immune system identify these cancers and destroy them. This is a long and expensive operation for vaccine manufacturers. But for Scancell's ImmunoBody this is easy. By making small alterations in ImmunoBody's DNA code it can be easily reprogrammed to generate new vaccines to treat different cancers in a matter of weeks. Scancell calls this feature, ImmunoBody's `plug and play' epitope expression vector system.
The directors plan to sell Scancell when SCIB1's clinical trials are completed.
Scancell is a great investment opportunity. The company makes unique reprogrammable vaccines to fight cancer. That's right, reprogrammable!
Scancell's vaccines are based on small pieces of DNA that program a patient's dendritic cells to make mimics of certain chemicals found in the particular cancer that the patient is suffering from. These chemical markers are then shown to the immune system's Killer T Cells which use them, like a bloodhound, to sniff out cancer and destroy it.
Scancell's technology is called ImmunoBody and the first vaccine of this type, code named SCIB1, is designed to treat skin cancer. This vaccine is intended to be a 'showcase vaccine' to display the ability of ImmunoBody to combat the disease.
Because some cancers display different chemical markers, new vaccines need to be designed to help the immune system identify these cancers and destroy them. This is a long and expensive operation for vaccine manufacturers. But for Scancell's ImmunoBody this is easy. By making small alterations in ImmunoBody's DNA code it can be easily reprogrammed to generate new vaccines to treat different cancers in a matter of weeks. Scancell calls this feature, ImmunoBody's `plug and play' epitope expression vector system.
The directors plan to sell Scancell when SCIB1's clinical trials are completed.
Antwort auf Beitrag Nr.: 44.134.271 von IronSioux am 13.02.13 09:09:23Re: SCANCELL'S RISE IS DENDREON'S DOOM!
It seems that IronSioux is not the only who thinks that Scancell will snatch Dendreon's crown. Here is a link to a post on the Dendreon Board of America's InvestorsHub:
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
It seems that IronSioux is not the only who thinks that Scancell will snatch Dendreon's crown. Here is a link to a post on the Dendreon Board of America's InvestorsHub:
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Antwort auf Beitrag Nr.: 45.354.633 von Robofrau am 30.08.13 09:43:57I apologize, my link didn't work. I forgot to use the 'Link' tab. I shall try again.
Here is a link to a post written in America by an investor who sold his shares in Dendreon so he could buy Scancell's shares instead:
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Here is a link to a post written in America by an investor who sold his shares in Dendreon so he could buy Scancell's shares instead:
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…
Trading Spotlight
Can someone please tell me what the price drivers are for this share going forward?
Antwort auf Beitrag Nr.: 45.356.587 von Robofrau am 30.08.13 12:51:53Robofrau,
I think the next big price driver will be the announcement of the details of Scancell's new vaccine technology - Moditope - in about five weeks time. This is expected to happen at a presentation for shareholders in the first week of October.
Moditope consists of the discovery by Scancell of a series of modified epitopes (those parts of viral and cancer antigens actually recognized by the immune system). These Moditope epitopes generate a special kind of Killer T Cell called a CD4 Killer T Cell. The usually type of Killer T Cell is the CD8 Killer T Cell. CD4 cells normally function as helper cells not killer cells.
This is the first time that scientists have found a practical way of generating this type of CD4 cell. CD4 Killer T Cells are far more potent and long lasting than the ordinary CD8 Killer T Cells that are stimulated to attack viruses and cancers by today's vaccines. Scancell intends to offer these patented modified epitopes to other manufacturers of vaccines as well as developing Moditope enhanced vaccines themselves.
Scancell originally announced their Moditope discovery in August 2012 but very few details were supplied at the time. During the last year Scancell has been adding all the details to their patent document. They had one year exactly to do this before filing. Now they are preparing to announce these details for the first time.
I think the next big price driver will be the announcement of the details of Scancell's new vaccine technology - Moditope - in about five weeks time. This is expected to happen at a presentation for shareholders in the first week of October.
Moditope consists of the discovery by Scancell of a series of modified epitopes (those parts of viral and cancer antigens actually recognized by the immune system). These Moditope epitopes generate a special kind of Killer T Cell called a CD4 Killer T Cell. The usually type of Killer T Cell is the CD8 Killer T Cell. CD4 cells normally function as helper cells not killer cells.
This is the first time that scientists have found a practical way of generating this type of CD4 cell. CD4 Killer T Cells are far more potent and long lasting than the ordinary CD8 Killer T Cells that are stimulated to attack viruses and cancers by today's vaccines. Scancell intends to offer these patented modified epitopes to other manufacturers of vaccines as well as developing Moditope enhanced vaccines themselves.
Scancell originally announced their Moditope discovery in August 2012 but very few details were supplied at the time. During the last year Scancell has been adding all the details to their patent document. They had one year exactly to do this before filing. Now they are preparing to announce these details for the first time.
Was die Zeitungen sagen:
Finanz und Wirtschaft - 12. Juni 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/Finanz%20und%20W…
ECOreporter.com - 14. August 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/130814ECOreporte…
eyeonthemoney sagt:
«Diesen Pennystock müssen Sie kaufen!»
Finanz und Wirtschaft - 12. Juni 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/Finanz%20und%20W…
ECOreporter.com - 14. August 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/130814ECOreporte…
eyeonthemoney sagt:
«Diesen Pennystock müssen Sie kaufen!»
Antwort auf Beitrag Nr.: 45.363.429 von eyeonthemoney am 31.08.13 23:13:46Was die Zeitungen sagen:
Finanz und Wirtschaft - 12. Juni 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/Finanz%20und%20W…
ECOreporter.com - 14. August 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/130814ECOreporte…
eyeonthemoney sagt:
«Diesen Pennystock müssen Sie kaufen!»
Finanz und Wirtschaft - 12. Juni 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/Finanz%20und%20W…
ECOreporter.com - 14. August 2013
http://www.scancell.co.uk/AssetLibrary/PDFs/130814ECOreporte…
eyeonthemoney sagt:
«Diesen Pennystock müssen Sie kaufen!»
Antwort auf Beitrag Nr.: 45.357.421 von fernendonner am 30.08.13 14:37:33Fernendonner,
Thank you for your helpful response. I have been doing some research into Scancell's Moditope technology. It seems that Scancell's discovery will be very important and help many vaccines around the world work much more powerfully.
This is what is said on Scancell's website:
STIMULATION OF KILLER CD4 T CELLS WITH POTENT ANTI-TUMOUR ACTIVITY
15 August 2012
Scancell Holdings Plc
(‘Scancell’)
Moditope vaccine technology platform
Stimulation of killer CD4 T cells with potent anti-tumour activity
Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces the development of a new platform technology (Moditope) that stimulates the production of killer CD4 T cells with powerful anti-tumour activity. The Directors believe that this new discovery could have a profound effect on the way that cancer vaccines are developed.
CD4 responses to cancer associated antigens have been notoriously difficult to generate whether presented as peptides, proteins or DNA. CD4 cells are vital for effective anti-tumour immunity. Scancell has identified and patented a series of modified epitopes that overcome this limitation. Scancell’s Moditope technology produces killer CD4 T cells that destroy tumours without toxicity
Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented: “Not only do these unique epitopes stimulate a CD4 killer T cell response, we have also shown in tests that cancer patients can produce an immune response to these epitopes. The Moditope epitopes can be used to develop both DNA and peptide vaccines and could become an important component of many therapeutic vaccines in the future, both under development at Scancell and other companies”
Prof Peter Stern, Head of the Cancer Research UK, Immunology Group at the Paterson Institute for Cancer Research, commented: “This novel technology has the potential to transform the therapeutic cancer field. It is increasingly recognised that combining products and technologies will unlock the full potential of cancer vaccines. The Moditope technology offers those developing cancer vaccines, a means to optimise the potency of their immune targets”.
David Evans, Chairman of Scancell Holdings, commented: "This highly innovative discovery opens up a new approach to the development of cancer vaccines. Whilst currently at an early stage, we are aware that the opportunities could be considerable in addition to Scancell’s existing platform technology. As a result, the Board is actively evaluating its strategic options for this new technology platform and will be consulting with key shareholders in this regard. We are excited by the potential and are resolute in our aim of creating the greatest value for shareholders. The Board will update the market in due course.”
http://www.scancell.co.uk/Apps/Content/News/?id=252
Thank you for your helpful response. I have been doing some research into Scancell's Moditope technology. It seems that Scancell's discovery will be very important and help many vaccines around the world work much more powerfully.
This is what is said on Scancell's website:
STIMULATION OF KILLER CD4 T CELLS WITH POTENT ANTI-TUMOUR ACTIVITY
15 August 2012
Scancell Holdings Plc
(‘Scancell’)
Moditope vaccine technology platform
Stimulation of killer CD4 T cells with potent anti-tumour activity
Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces the development of a new platform technology (Moditope) that stimulates the production of killer CD4 T cells with powerful anti-tumour activity. The Directors believe that this new discovery could have a profound effect on the way that cancer vaccines are developed.
CD4 responses to cancer associated antigens have been notoriously difficult to generate whether presented as peptides, proteins or DNA. CD4 cells are vital for effective anti-tumour immunity. Scancell has identified and patented a series of modified epitopes that overcome this limitation. Scancell’s Moditope technology produces killer CD4 T cells that destroy tumours without toxicity
Professor Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented: “Not only do these unique epitopes stimulate a CD4 killer T cell response, we have also shown in tests that cancer patients can produce an immune response to these epitopes. The Moditope epitopes can be used to develop both DNA and peptide vaccines and could become an important component of many therapeutic vaccines in the future, both under development at Scancell and other companies”
Prof Peter Stern, Head of the Cancer Research UK, Immunology Group at the Paterson Institute for Cancer Research, commented: “This novel technology has the potential to transform the therapeutic cancer field. It is increasingly recognised that combining products and technologies will unlock the full potential of cancer vaccines. The Moditope technology offers those developing cancer vaccines, a means to optimise the potency of their immune targets”.
David Evans, Chairman of Scancell Holdings, commented: "This highly innovative discovery opens up a new approach to the development of cancer vaccines. Whilst currently at an early stage, we are aware that the opportunities could be considerable in addition to Scancell’s existing platform technology. As a result, the Board is actively evaluating its strategic options for this new technology platform and will be consulting with key shareholders in this regard. We are excited by the potential and are resolute in our aim of creating the greatest value for shareholders. The Board will update the market in due course.”
http://www.scancell.co.uk/Apps/Content/News/?id=252
TODAY'S NEWS: DNA IMMUNOBODY® PATENT APPROVED IN AUSTRALIA
RNS Number : 0587N
Scancell Holdings Plc
03 September 2013
3 September 2013
Scancell Holdings Plc
('Scancell')
DNA ImmunoBody® Patent Granted in first market
Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in Australia. This is the first jurisdiction to approve the DNA patent and is a key landmark on the road to comprehensively protecting Scancell's DNA ImmunoBody® platform technology.
The patent, which covers the DNA ImmunoBody® platform technology and is of importance for the protection of Scancell's entire pipeline of ImmunoBody® vaccines, has also been filed in the US, Europe and other major markets. The composition of matter patent for SCIB1, Scancell's ImmunoBody® vaccine for the treatment of melanoma, has already been granted in Europe, Turkey and South Africa.
Scancell's protein ImmunoBody® patent has been approved in the US, Europe, Japan and Australia.
Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:
"Our lead ImmunoBody® for melanoma, SCIB1, currently in Phase I/II clinical trials is based on the DNA approach. The approval of this DNA patent is therefore a very important step in the development and commercialisation of our ImmunoBody® platform. Scancell continues to build its growing portfolio of intellectual property in parallel with advancing the clinical trial programme on SCIB1."
-ENDS-
RNS Number : 0587N
Scancell Holdings Plc
03 September 2013
3 September 2013
Scancell Holdings Plc
('Scancell')
DNA ImmunoBody® Patent Granted in first market
Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in Australia. This is the first jurisdiction to approve the DNA patent and is a key landmark on the road to comprehensively protecting Scancell's DNA ImmunoBody® platform technology.
The patent, which covers the DNA ImmunoBody® platform technology and is of importance for the protection of Scancell's entire pipeline of ImmunoBody® vaccines, has also been filed in the US, Europe and other major markets. The composition of matter patent for SCIB1, Scancell's ImmunoBody® vaccine for the treatment of melanoma, has already been granted in Europe, Turkey and South Africa.
Scancell's protein ImmunoBody® patent has been approved in the US, Europe, Japan and Australia.
Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:
"Our lead ImmunoBody® for melanoma, SCIB1, currently in Phase I/II clinical trials is based on the DNA approach. The approval of this DNA patent is therefore a very important step in the development and commercialisation of our ImmunoBody® platform. Scancell continues to build its growing portfolio of intellectual property in parallel with advancing the clinical trial programme on SCIB1."
-ENDS-
Aktuelle News zur SCANCELL Aktie
http://www.finanznachrichten.de/nachrichten-aktien/scancell-…
http://www.finanznachrichten.de/nachrichten-aktien/scancell-…
SCANCELL HAS PATENT GRANTED
03/09/2013 Harriet Russell
Developer of cancer treatment therapies Scancell Holdings (LON:SCLP) has had a patent granted in Australia.
It is the first jurisdiction to approve a patent for the company's DNA Immunobody technology platform although the US, Europe, Japan and Australia have all previously approved a protein Immunobody patent.
The latest patent, which covers the DNA ImmunoBody platform technology has also been filed in the US and Europe as well as 'other major markets' which the company did not specify.
Furthermore, the 'composition of matter' patent for SCIB1, Scancell's ImmunoBody vaccine for the treatment of melanoma, has already been granted in Europe, Turkey and South Africa.
Chief executive Richard Goodfellow confirmed that the SCIB1 compound is currently undergoing clinical trials and 'is based on a DNA approach', making the latest patent approval 'very important'.
Shares in Scancell Holdings were up 6.7 per cent this morning to 35.8p, valuing the company at £74.8 million.
http://www.growthcompany.co.uk/news/2392663/scancell-has-pat…
03/09/2013 Harriet Russell
Developer of cancer treatment therapies Scancell Holdings (LON:SCLP) has had a patent granted in Australia.
It is the first jurisdiction to approve a patent for the company's DNA Immunobody technology platform although the US, Europe, Japan and Australia have all previously approved a protein Immunobody patent.
The latest patent, which covers the DNA ImmunoBody platform technology has also been filed in the US and Europe as well as 'other major markets' which the company did not specify.
Furthermore, the 'composition of matter' patent for SCIB1, Scancell's ImmunoBody vaccine for the treatment of melanoma, has already been granted in Europe, Turkey and South Africa.
Chief executive Richard Goodfellow confirmed that the SCIB1 compound is currently undergoing clinical trials and 'is based on a DNA approach', making the latest patent approval 'very important'.
Shares in Scancell Holdings were up 6.7 per cent this morning to 35.8p, valuing the company at £74.8 million.
http://www.growthcompany.co.uk/news/2392663/scancell-has-pat…
Here is a new report about Scancell from Dr. Reuter:
http://www.dr-reuter.eu/download.php?document=WEBDLsslsaug20…
http://www.dr-reuter.eu/download.php?document=WEBDLsslsaug20…
RNS Number : 6546N
Scancell Holdings Plc
10 September 2013
10 September 2013
Scancell Holdings Plc
('Scancell')
INVESTOR UPDATE
Interactive panel discussion, led by Professor Karol Sikora
Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013.
Joint CEO's, Dr Richard Goodfellow and Professor Lindy Durrant will present an update on Scancell's SCIB1 trial and an introduction to their new Moditope™ platform. Specialist guest speakers, led by Professor Karol Sikora, will form an interactive panel to discuss how the natural immune system can be harnessed to eradicate tumour cells and the prospects for this emerging class of immunotherapies as effective treatments for cancer. The event will be followed by a lunch.
Scancell is developing novel therapeutic vaccines for the treatment of cancer based on its ground-breaking ImmunoBody® and Moditope™ technology platforms.
Scancell's first cancer vaccine SCIB1 is being developed for the treatment of malignant melanoma and is in Phase 1/2 clinical trials. Encouraging results from the Phase 1 part of the study provided the first evidence that Scancell's ImmunoBody® vaccine approach is producing an immune response in cancer patients which may also be associated with clinical benefit. In view of the positive results and minimal side effects seen with the 4 mg dose (Part 1) the Company has initiated evaluation of an 8 mg dose in parallel with Part 2 of the study.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer immune cells that destroy tumours without toxicity. This Moditope™ platform has the potential to generate a completely new class of potent and selective immunotherapy agents and could have a profound effect on the way that cancer vaccines are developed. In particular, the technology can overcome the immune suppression induced by tumours themselves without the need for checkpoint blockade inhibitors (for example CTLA4 antibodies and PD-1 inhibitors), thereby allowing activated T cells seek out and kill tumour cells that would otherwise be hidden from the immune system.
For further details of the event, please contact Mo Noonan or Eleanor Clarke at FTI Consulting.
-ENDS-
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
This information is provided by RNS - The company news service from the London Stock Exchange.
Scancell Holdings Plc
10 September 2013
10 September 2013
Scancell Holdings Plc
('Scancell')
INVESTOR UPDATE
Interactive panel discussion, led by Professor Karol Sikora
Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013.
Joint CEO's, Dr Richard Goodfellow and Professor Lindy Durrant will present an update on Scancell's SCIB1 trial and an introduction to their new Moditope™ platform. Specialist guest speakers, led by Professor Karol Sikora, will form an interactive panel to discuss how the natural immune system can be harnessed to eradicate tumour cells and the prospects for this emerging class of immunotherapies as effective treatments for cancer. The event will be followed by a lunch.
Scancell is developing novel therapeutic vaccines for the treatment of cancer based on its ground-breaking ImmunoBody® and Moditope™ technology platforms.
Scancell's first cancer vaccine SCIB1 is being developed for the treatment of malignant melanoma and is in Phase 1/2 clinical trials. Encouraging results from the Phase 1 part of the study provided the first evidence that Scancell's ImmunoBody® vaccine approach is producing an immune response in cancer patients which may also be associated with clinical benefit. In view of the positive results and minimal side effects seen with the 4 mg dose (Part 1) the Company has initiated evaluation of an 8 mg dose in parallel with Part 2 of the study.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer immune cells that destroy tumours without toxicity. This Moditope™ platform has the potential to generate a completely new class of potent and selective immunotherapy agents and could have a profound effect on the way that cancer vaccines are developed. In particular, the technology can overcome the immune suppression induced by tumours themselves without the need for checkpoint blockade inhibitors (for example CTLA4 antibodies and PD-1 inhibitors), thereby allowing activated T cells seek out and kill tumour cells that would otherwise be hidden from the immune system.
For further details of the event, please contact Mo Noonan or Eleanor Clarke at FTI Consulting.
-ENDS-
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
This information is provided by RNS - The company news service from the London Stock Exchange.
New Video Interview with Scancell's Joint CEO, Prof Lindy Durrant:
http://www.brrmedia.co.uk/event/116763/partner/scancell
http://www.brrmedia.co.uk/event/116763/partner/scancell
Einladung zur Webkonferenz 4SC AG und Scancell plc
Liebe Biotech-Interessierte, liebe Freunde und Interessenten der Unternehmen 4SC und Scancell,
hiermit laden wir Sie herzlich am Donnerstag den 17.10.2013 um 15 Uhr zu einer kostenlosen Investoren-Webkonferenz mit Herrn Enno Spillner (CEO, 4SC AG) und Richard Goodfellow (CEO, Scancell plc) ein.
4SC hat sich auf die Erforschung und Entwicklung innovativer zielgerichteter Therapien zur Behandlung von Krebs und Autoimmunerkrankungen spezialisiert. Enno Spillner, CEO & CFO der 4SC AG, wird ein Update zu den Entwicklungsaktivitäten des Unternehmens geben, insbesondere zu der geplanten Zulassungsstudie mit dem Krebswirkstoff Resminostat in der Indikation Leberkrebs.
Außerdem wird Richard Goodfellow, CEO des britischen Biotech-Unternehmens Scancell plc, Entwickler neuartiger Immuntherapien zur Behandlung von Krebs, ein Update zu Scancells vielversprechenden Plattformtechnologien Moditope und Immunobody geben.
Um Ihre persönlichen Fragen an Herrn Spillner und Herrn Goodfellow stellen zu können, haben Sie die Möglichkeit den Chat von Spreed zu nutzen.
Einwahllink: https://eu42.spreed.com/checkin/jc/623244642
Damit wir im Vorfeld die Teilnahme besser abschätzen können, melden Sie sich unverbindlich unter m.glomb@dr-reuter.eu an.
Liebe Biotech-Interessierte, liebe Freunde und Interessenten der Unternehmen 4SC und Scancell,
hiermit laden wir Sie herzlich am Donnerstag den 17.10.2013 um 15 Uhr zu einer kostenlosen Investoren-Webkonferenz mit Herrn Enno Spillner (CEO, 4SC AG) und Richard Goodfellow (CEO, Scancell plc) ein.
4SC hat sich auf die Erforschung und Entwicklung innovativer zielgerichteter Therapien zur Behandlung von Krebs und Autoimmunerkrankungen spezialisiert. Enno Spillner, CEO & CFO der 4SC AG, wird ein Update zu den Entwicklungsaktivitäten des Unternehmens geben, insbesondere zu der geplanten Zulassungsstudie mit dem Krebswirkstoff Resminostat in der Indikation Leberkrebs.
Außerdem wird Richard Goodfellow, CEO des britischen Biotech-Unternehmens Scancell plc, Entwickler neuartiger Immuntherapien zur Behandlung von Krebs, ein Update zu Scancells vielversprechenden Plattformtechnologien Moditope und Immunobody geben.
Um Ihre persönlichen Fragen an Herrn Spillner und Herrn Goodfellow stellen zu können, haben Sie die Möglichkeit den Chat von Spreed zu nutzen.
Einwahllink: https://eu42.spreed.com/checkin/jc/623244642
Damit wir im Vorfeld die Teilnahme besser abschätzen können, melden Sie sich unverbindlich unter m.glomb@dr-reuter.eu an.
Haben Sie die WebKonferenz mit Scancell & 4SC verpasst?
Keine Sorge!
Hier können Sie sich die WebKonferenz abrufen:
http://www.brrmedia.co.uk/event/117344/dr-richard-goodfellow…
Keine Sorge!
Hier können Sie sich die WebKonferenz abrufen:
http://www.brrmedia.co.uk/event/117344/dr-richard-goodfellow…
Britische Börsenguru Zak Mir sieht Kursziel von 0.70 €
http://www.tradersown.co.uk/magazine/read/scancell-holdings-…
http://www.tradersown.co.uk/magazine/read/scancell-holdings-…
Scancell Aktie auf dem Vormarsch!!!! 
Eine unglaubliche Geschichte: Mädchen mit Scancell-Impfstoff geheilt!
http://www.express.co.uk/posts/view/175410/Cancer-scientists…
http://www.express.co.uk/posts/view/175410/Cancer-scientists…
Das ist aus Mai 2010. Ich glaube nicht, dass das heute noch etwas an der Geschäftsentwicklung ändern wird.
Womit ich nicht sagen möchte, dass die Entwicklung unbedingt negativ sein wird.
Womit ich nicht sagen möchte, dass die Entwicklung unbedingt negativ sein wird.
Scancell-Impfstoff gegen Hautkrebs: Erfolgreiche Schritte auf dem Weg zur Therapie
http://www.thesundaytimes.co.uk/sto/business/Tech_and_Media/…
http://www.thesundaytimes.co.uk/sto/business/Tech_and_Media/…
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Spam, Werbung!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Spam, Werbung
Scancell-Impfstoff übertrifft alle Erwartungen!
RNS Number : 9752U
Scancell Holdings Plc
09 December 2013
9 December 2013
Scancell Holdings Plc
Compelling new immune response data and promising survival trend suggest potential for SCIB1 as an effective novel therapy in metastatic melanoma
Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce encouraging results from Part 2 of its on-going Phase 1/2 clinical trial in patients with Stage III/IV melanoma treated with the SCIB1 ImmunoBodyÒ as well as an update from patients in Part 1 of the study.
Highlights
Part 2 study results
· All 14 study patients produced a melanoma-specific T-cell response to treatment
· All patients are still alive; only three patients have any evidence of disease progression
· Median survival time of Part 2 patients since initiating treatment is currently 15 months; 21 months since diagnosis of metastatic disease
· Six patients are continuing on extended, long-term treatment with SCIB1
· SCIB1 therapy was well tolerated with no reports of serious drug-related side effects in line with results reported from Part 1 of the study
Part 1 study update
· The four patients who were alive at the time of the initial Part 1 report (December 2012) remain alive
· Median survival time in Part 1 patients who received at least three treatments with the 2mg/4mg doses of SCIB1 is now 25 months
These results confirm that Scancell's SCIB1 ImmunoBodyÒ therapy is producing a melanoma-specific immune response in patients with Stage III/IV melanoma. This is particularly evident in patients with resected disease. Together with the immunological and clinical data from Part 1 of the study, the results suggest that these induced immune responses might also be contributing to the control of tumour in these patients.
Prof Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented:
"These results exceeded our highest expectations confirming that SCIB1 induces a consistent melanoma-specific immune response in Stage III/IV melanoma patients, especially in those with resected disease. Whilst the numbers are still small, it suggests that SCIB1 may be contributing to prolonged survival by controlling tumour growth and supports our belief that the highly targeted ImmunoBody® approach generates potent and specific T cells that can control malignant disease."
Prof Poulam Patel, the principal investigator in the trial and Prof of Clinical Oncology at the University of Nottingham, added:
"This promising new data further supports our hypothesis that SCIB1 can harness the body's own immune system to control metastatic melanoma in a safe and effective way. More generally it also adds to the growing belief that training T cells to target and control tumour growth is one of the most promising new ways of treating cancer. In patients with more extensive metastases, it is feasible that combining SCIB1 with the latest checkpoint inhibitor drugs, which allow T cells to work better within the tumour environment, may offer further patient benefit."
Study Design
The first part of this single arm, open label, Phase 1/2 clinical trial was conducted in five UK centres in 11 patients, ten with Stage IV and one with Stage III malignant melanoma. Patients were to be given five doses of 0.4mg, 2mg or 4mg of SCIB1, delivered by Ichor Medical Systems' TriGrid™ electroporation delivery device, over a period of sixmonths. One patient in the 0.4mg dose group and one in the 4mg dose group who received only a single dose of SCIB1 were withdrawn from the study due to progressive disease shortly after study entry and were replaced to ensure that at least three patients in each dose cohort could be fully evaluated for immune response. During the course of the study, regulatory approval was granted to increase the SCIB1 dose from 2mg to 4mg in patients in the 2mg cohort, if the treatment was well tolerated. Two patients in this group received two 4mg doses of SCIB1 and onepatient received a single 4mg dose. Regulatory approval was subsequently obtained for treating a cohort of patients with 8mg of drug. Dosing of these patients is currently on-going.
In Part 2 of the study, 14 patients with resected Stage III/IV melanoma (eight with Stage III and six with Stage IV) entered the study. One patient was only able to tolerate three doses of 2mg and withdrew from the study. Of the remaining patients, 12 received a full 4mg dose of SCIB1 on five occasions over a period of 6 months and one received four doses of 4mg and one dose of 2mg.
During the course of the study, regulatory approval was granted to continue treating eligible patients for a period of up to 5 years from the formal end of the study. During this period patients can receive a 4mg dose of SCIB1 every 3-6 months.
Clinical response
Part 1
Four out of the six patients in the 2mg/4mg cohorts who received at least three doses of SCIB1 are still alive and one remains disease-free more than 2 years after starting treatment. All of the patients in the 0.4mg dose group have died from melanoma progression. The median survival time for the six evaluable patients in the 2mg/4mg cohorts is currently 25 months.
One patient in the 4mg dose group with multiple tumour lesions present at the start of treatment showed a "differential response" pattern in which all of her lung lesions decreased in size or disappeared completely following six months of treatment with SCIB1 whereas one abdominal wall tumour nodule grew and was resected. Staining of tissue taken from the resected nodule showed it had lost expression of one of the target melanoma antigens, gp100, but had high levels of PD-1 protein, which is known to attenuate high avidity T cell responses; this suggests that combining SCIB1 treatment with anti-PD-1 monoclonal antibodies may be an effective therapeutic approach. The patient continued on extended treatment with SCIB1 until she was subsequently found to have recurrent melanoma in her intestines; this tumour was also excised and treatment was discontinued.
Part 2
All of the resected Stage III/IV patients treated with SCIB1 in Part 2 remain alive and only three have had progressive disease to date. One patient had their lesion excised in January 2013 and has no further disease progression to date. The other two patients have progressed within the last month. The median survival time for Part 2 patients is currently 15 months from study entry and 21 months from diagnosis of metastatic disease.
Immune response
Immune response was measured by peptide-specific proliferation. A positive response required at least twice the background control at each time point and at least twice the pre-treatment control value on two or more of the six time points measured. In addition, responses were assessed using an enzyme-linked immunosorbent (ELISPOT) assay after T cell expansion in vitro, where a positive response was more than three standard deviations above the pre-treatment control value on two or more of the six time points measured. Fresh samples were analysed in both assays, except for one patient where the controls for the fresh proliferation assay were not validated and the assay was repeated using frozen samples.
Part 1
One patient in the 0.4mg cohort, all three patients in the 2mg/4mg dose cohort and two patients in the 4mg dose cohort mounted a measurable proliferation response to the melanoma-specific epitopes in SCIB1. In addition, the patient with the differential clinical response was assessed using the ELISPOT assay and made a strong response to the melanoma TRP-2 antigen.
Part 2
All 14 patients responded to treatment in either the proliferation or ELISPOT assay. Twelve patients were immune responders in the proliferation assay, 13 patients responded in the ELISPOT assay and 11 patients responded in both assays, including the patient who only received three doses of 2mg of SCIB1. Broad, high frequency responses were seen against both the two CD8+ T cell epitopes and against the two CD4+ T cell epitopes. Six patients responded to all four epitopes, five patients responded to three epitopes and three patients responded to two epitopes. Statistically significant responses (p>0.0001) were seen after three, four or five immunisations but not after two, indicating that at least three doses are required for a strong immune response to develop.
Due to these encouraging results six patients are continuing on extended, long-term treatment with SCIB1.
Tolerability and Safety
The SCIB1 immunotherapy produced very few side effects, none of which were serious, with no new or unexpected issues found over those reported with the results from Part 1 of the study where no systemic dose-limiting toxicities were observed. The most commonly reported adverse events were injection site reactions and cold- and flu-like symptoms. The electroporation procedure itself was less well-tolerated in some patients and, in certain cases, required pre-treatment sedation. However, only one patient has withdrawn from the study for this reason and seven chose to continue treatment in Part 2 of the study (one has since discontinued).
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
This information is provided by RNS, the company news service from the London Stock Exchange
http://www.scancell.co.uk/Apps/Content/News/?id=305
RNS Number : 9752U
Scancell Holdings Plc
09 December 2013
9 December 2013
Scancell Holdings Plc
Compelling new immune response data and promising survival trend suggest potential for SCIB1 as an effective novel therapy in metastatic melanoma
Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce encouraging results from Part 2 of its on-going Phase 1/2 clinical trial in patients with Stage III/IV melanoma treated with the SCIB1 ImmunoBodyÒ as well as an update from patients in Part 1 of the study.
Highlights
Part 2 study results
· All 14 study patients produced a melanoma-specific T-cell response to treatment
· All patients are still alive; only three patients have any evidence of disease progression
· Median survival time of Part 2 patients since initiating treatment is currently 15 months; 21 months since diagnosis of metastatic disease
· Six patients are continuing on extended, long-term treatment with SCIB1
· SCIB1 therapy was well tolerated with no reports of serious drug-related side effects in line with results reported from Part 1 of the study
Part 1 study update
· The four patients who were alive at the time of the initial Part 1 report (December 2012) remain alive
· Median survival time in Part 1 patients who received at least three treatments with the 2mg/4mg doses of SCIB1 is now 25 months
These results confirm that Scancell's SCIB1 ImmunoBodyÒ therapy is producing a melanoma-specific immune response in patients with Stage III/IV melanoma. This is particularly evident in patients with resected disease. Together with the immunological and clinical data from Part 1 of the study, the results suggest that these induced immune responses might also be contributing to the control of tumour in these patients.
Prof Lindy Durrant, Joint CEO of Scancell Holdings and Professor of Cancer Immunotherapy at Nottingham University, commented:
"These results exceeded our highest expectations confirming that SCIB1 induces a consistent melanoma-specific immune response in Stage III/IV melanoma patients, especially in those with resected disease. Whilst the numbers are still small, it suggests that SCIB1 may be contributing to prolonged survival by controlling tumour growth and supports our belief that the highly targeted ImmunoBody® approach generates potent and specific T cells that can control malignant disease."
Prof Poulam Patel, the principal investigator in the trial and Prof of Clinical Oncology at the University of Nottingham, added:
"This promising new data further supports our hypothesis that SCIB1 can harness the body's own immune system to control metastatic melanoma in a safe and effective way. More generally it also adds to the growing belief that training T cells to target and control tumour growth is one of the most promising new ways of treating cancer. In patients with more extensive metastases, it is feasible that combining SCIB1 with the latest checkpoint inhibitor drugs, which allow T cells to work better within the tumour environment, may offer further patient benefit."
Study Design
The first part of this single arm, open label, Phase 1/2 clinical trial was conducted in five UK centres in 11 patients, ten with Stage IV and one with Stage III malignant melanoma. Patients were to be given five doses of 0.4mg, 2mg or 4mg of SCIB1, delivered by Ichor Medical Systems' TriGrid™ electroporation delivery device, over a period of sixmonths. One patient in the 0.4mg dose group and one in the 4mg dose group who received only a single dose of SCIB1 were withdrawn from the study due to progressive disease shortly after study entry and were replaced to ensure that at least three patients in each dose cohort could be fully evaluated for immune response. During the course of the study, regulatory approval was granted to increase the SCIB1 dose from 2mg to 4mg in patients in the 2mg cohort, if the treatment was well tolerated. Two patients in this group received two 4mg doses of SCIB1 and onepatient received a single 4mg dose. Regulatory approval was subsequently obtained for treating a cohort of patients with 8mg of drug. Dosing of these patients is currently on-going.
In Part 2 of the study, 14 patients with resected Stage III/IV melanoma (eight with Stage III and six with Stage IV) entered the study. One patient was only able to tolerate three doses of 2mg and withdrew from the study. Of the remaining patients, 12 received a full 4mg dose of SCIB1 on five occasions over a period of 6 months and one received four doses of 4mg and one dose of 2mg.
During the course of the study, regulatory approval was granted to continue treating eligible patients for a period of up to 5 years from the formal end of the study. During this period patients can receive a 4mg dose of SCIB1 every 3-6 months.
Clinical response
Part 1
Four out of the six patients in the 2mg/4mg cohorts who received at least three doses of SCIB1 are still alive and one remains disease-free more than 2 years after starting treatment. All of the patients in the 0.4mg dose group have died from melanoma progression. The median survival time for the six evaluable patients in the 2mg/4mg cohorts is currently 25 months.
One patient in the 4mg dose group with multiple tumour lesions present at the start of treatment showed a "differential response" pattern in which all of her lung lesions decreased in size or disappeared completely following six months of treatment with SCIB1 whereas one abdominal wall tumour nodule grew and was resected. Staining of tissue taken from the resected nodule showed it had lost expression of one of the target melanoma antigens, gp100, but had high levels of PD-1 protein, which is known to attenuate high avidity T cell responses; this suggests that combining SCIB1 treatment with anti-PD-1 monoclonal antibodies may be an effective therapeutic approach. The patient continued on extended treatment with SCIB1 until she was subsequently found to have recurrent melanoma in her intestines; this tumour was also excised and treatment was discontinued.
Part 2
All of the resected Stage III/IV patients treated with SCIB1 in Part 2 remain alive and only three have had progressive disease to date. One patient had their lesion excised in January 2013 and has no further disease progression to date. The other two patients have progressed within the last month. The median survival time for Part 2 patients is currently 15 months from study entry and 21 months from diagnosis of metastatic disease.
Immune response
Immune response was measured by peptide-specific proliferation. A positive response required at least twice the background control at each time point and at least twice the pre-treatment control value on two or more of the six time points measured. In addition, responses were assessed using an enzyme-linked immunosorbent (ELISPOT) assay after T cell expansion in vitro, where a positive response was more than three standard deviations above the pre-treatment control value on two or more of the six time points measured. Fresh samples were analysed in both assays, except for one patient where the controls for the fresh proliferation assay were not validated and the assay was repeated using frozen samples.
Part 1
One patient in the 0.4mg cohort, all three patients in the 2mg/4mg dose cohort and two patients in the 4mg dose cohort mounted a measurable proliferation response to the melanoma-specific epitopes in SCIB1. In addition, the patient with the differential clinical response was assessed using the ELISPOT assay and made a strong response to the melanoma TRP-2 antigen.
Part 2
All 14 patients responded to treatment in either the proliferation or ELISPOT assay. Twelve patients were immune responders in the proliferation assay, 13 patients responded in the ELISPOT assay and 11 patients responded in both assays, including the patient who only received three doses of 2mg of SCIB1. Broad, high frequency responses were seen against both the two CD8+ T cell epitopes and against the two CD4+ T cell epitopes. Six patients responded to all four epitopes, five patients responded to three epitopes and three patients responded to two epitopes. Statistically significant responses (p>0.0001) were seen after three, four or five immunisations but not after two, indicating that at least three doses are required for a strong immune response to develop.
Due to these encouraging results six patients are continuing on extended, long-term treatment with SCIB1.
Tolerability and Safety
The SCIB1 immunotherapy produced very few side effects, none of which were serious, with no new or unexpected issues found over those reported with the results from Part 1 of the study where no systemic dose-limiting toxicities were observed. The most commonly reported adverse events were injection site reactions and cold- and flu-like symptoms. The electroporation procedure itself was less well-tolerated in some patients and, in certain cases, required pre-treatment sedation. However, only one patient has withdrawn from the study for this reason and seven chose to continue treatment in Part 2 of the study (one has since discontinued).
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
This information is provided by RNS, the company news service from the London Stock Exchange
http://www.scancell.co.uk/Apps/Content/News/?id=305
The Directors believe....in the future
...dann doch lieber Dendreon
...dann doch lieber Dendreon
THE WALL STREET JOURNAL
LONDON--Scancell Holdings PLC (SCLP.LN), a developer of immunotherapies for the treatment of cancer, Monday said it is still aiming to sell the business at the earliest opportunity but will also consider revenue-generating deals in order to enhance the value of the company when it is eventually sold.
The company made the statement as it announced that immune response data from its lead program, the SCIB1 ImmunoBody immunotherapy for advanced melanoma, has exceeded its highest expectations and suggests that SCIB1 may be contributing to prolonged survival by controlling tumor growth.
"This data... makes (SCIB1) immediately much more attractive to a pharmaceutical partner," joint Chief Executive Dr. Richard Goodfellow told Dow Jones Newswires.
"What we always said is that while our short to medium-term aim is to sell the company as a whole, if we can enhance the value of the business... by doing a deal that will not compromise our ability to sell the business, we would certainly look at it," he added.
Earlier on Monday, Scancell said the latest data supports the company's hypothesis that SCIB1 can harness the body's own immune system to control metastatic melanoma.
Quelle:
http://online.wsj.com/article/BT-CO-20131209-703394.html?dsk…
LONDON--Scancell Holdings PLC (SCLP.LN), a developer of immunotherapies for the treatment of cancer, Monday said it is still aiming to sell the business at the earliest opportunity but will also consider revenue-generating deals in order to enhance the value of the company when it is eventually sold.
The company made the statement as it announced that immune response data from its lead program, the SCIB1 ImmunoBody immunotherapy for advanced melanoma, has exceeded its highest expectations and suggests that SCIB1 may be contributing to prolonged survival by controlling tumor growth.
"This data... makes (SCIB1) immediately much more attractive to a pharmaceutical partner," joint Chief Executive Dr. Richard Goodfellow told Dow Jones Newswires.
"What we always said is that while our short to medium-term aim is to sell the company as a whole, if we can enhance the value of the business... by doing a deal that will not compromise our ability to sell the business, we would certainly look at it," he added.
Earlier on Monday, Scancell said the latest data supports the company's hypothesis that SCIB1 can harness the body's own immune system to control metastatic melanoma.
Quelle:
http://online.wsj.com/article/BT-CO-20131209-703394.html?dsk…
Der Aktienanalyst Navid Malik von Cenkos Securities hat das Kursziel für Scancell von 127.89 pence (1.52 €) und die Einstufung auf "Buy" belassen.
http://uk.finance.yahoo.com/q?s=SCLP.L
http://uk.finance.yahoo.com/q?s=SCLP.L
Scancell could be the next big beneficiary of the spate of licensing deals currently being struck in the super hot area of Cancer Immunotherapy:
http://www.directorstalk.com/scancell-could-be-the-next-big-…
http://www.directorstalk.com/scancell-could-be-the-next-big-…
Scancell's SCIB1 vaccine granted FDA orphan drug status
Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, said the US Food and Drug Administration has granted orphan drug designation to its SCIB1 ImmunoBody for the treatment of metastatic melanoma.
Orphan drug status qualifies the development of SCIB1 for a 50% tax credit for clinical trials, a waiver of the prescription drug user fee for the drug approval procedure and a period of seven years of market exclusivity following drug approval by the FDA.
During the orphan market exclusivity period, the FDA cannot approve a NDA (new drug application) or a generic drug application for the same product including the principal molecular structure features of the drug and for the same rare disease indication.
http://www.stockmarketwire.com/article/4754073/Scancell-says…
Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, said the US Food and Drug Administration has granted orphan drug designation to its SCIB1 ImmunoBody for the treatment of metastatic melanoma.
Orphan drug status qualifies the development of SCIB1 for a 50% tax credit for clinical trials, a waiver of the prescription drug user fee for the drug approval procedure and a period of seven years of market exclusivity following drug approval by the FDA.
During the orphan market exclusivity period, the FDA cannot approve a NDA (new drug application) or a generic drug application for the same product including the principal molecular structure features of the drug and for the same rare disease indication.
http://www.stockmarketwire.com/article/4754073/Scancell-says…
Scancell Holdings PLC
18 Feb 2014 07:00:20
Scancell Hlds
RNS Number : 2822A
Scancell Holdings Plc
18 February 2014
18 February 2014
Scancell Holdings Plc
('Scancell' or the "Company")
Publication of Moditope® Patent
Scancell Holdings Plc, (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the publication of the patent application underpinning the Company's Moditope® platform. When granted, this patent will protect the platform to at least 2033.
The patent application, describes how the Moditope® immunotherapy platform harnesses CD4+ T cells to eradicate tumours. Moditope® deploys certain tumour-associated peptide epitopes as immunotherapeutic agents to overcome self-tolerance and eradicate tumour cells, with no requirement for blockade inhibitors. Planning is underway for the manufacture, preclinical testing and first-in-man clinical development of the Modi-1, the first Moditope® immunotherapeutic. The PCT patent application which has a priority date of 7 August 2012 was published on 13 February 2014 as WO2014/023957.
Prof. Lindy Durrant Professor of Cancer Immunotherapy at the University of Nottingham and Joint CEO of Scancell, said:
"The publication of the patent application is another important milestone in the development of a range of novel immunotherapeutics from the Moditope® platform. Recent data suggests that Modi-1 may exhibit potent anti-tumour effects even against established aggressive tumours, dramatically improving survival rates. We look forward to a busy and exciting year in which we continue to prepare Modi-1 for clinical trials which are on schedule to start in early 2016."
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
This information is provided by RNS, the company news service from the London Stock Exchange
END
http://www.londonstockexchange.com/exchange/news/market-news…
18 Feb 2014 07:00:20
Scancell Hlds
RNS Number : 2822A
Scancell Holdings Plc
18 February 2014
18 February 2014
Scancell Holdings Plc
('Scancell' or the "Company")
Publication of Moditope® Patent
Scancell Holdings Plc, (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the publication of the patent application underpinning the Company's Moditope® platform. When granted, this patent will protect the platform to at least 2033.
The patent application, describes how the Moditope® immunotherapy platform harnesses CD4+ T cells to eradicate tumours. Moditope® deploys certain tumour-associated peptide epitopes as immunotherapeutic agents to overcome self-tolerance and eradicate tumour cells, with no requirement for blockade inhibitors. Planning is underway for the manufacture, preclinical testing and first-in-man clinical development of the Modi-1, the first Moditope® immunotherapeutic. The PCT patent application which has a priority date of 7 August 2012 was published on 13 February 2014 as WO2014/023957.
Prof. Lindy Durrant Professor of Cancer Immunotherapy at the University of Nottingham and Joint CEO of Scancell, said:
"The publication of the patent application is another important milestone in the development of a range of novel immunotherapeutics from the Moditope® platform. Recent data suggests that Modi-1 may exhibit potent anti-tumour effects even against established aggressive tumours, dramatically improving survival rates. We look forward to a busy and exciting year in which we continue to prepare Modi-1 for clinical trials which are on schedule to start in early 2016."
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
This information is provided by RNS, the company news service from the London Stock Exchange
END
http://www.londonstockexchange.com/exchange/news/market-news…
Scancell's Moditope patent is published
http://www.euroinvestor.com/community/discussionthread.aspx?…
http://www.euroinvestor.com/community/discussionthread.aspx?…
Does Uncle Sam have designs on Scancell?
Its no secret, Scancell's directors plan to sell the British company sometime over the next few years. The Americans are probably the most interested of all in seeing the company cross the Atlantic as Scancell has been given the worldwide rights to use the US Department of Health's melanoma antigens in its lead vaccine, SCIB1. The US government can only get a return on these antigen discoveries when Scancell's vaccine enters the market-place. Scancell has agreed to pay royalties, which the Americans are keen to receive having spent years and millions of dollars developing the antigens at the National Cancer Institute in Bethesda, Maryland.
Here's an intriguing comment by one poster on London South East's Scancell Chat:
Politics! Politics!
The US government owns the melanoma antigens in Scancell's lead vaccine. To get a return on the millions of dollars they have spent developing them, they will be putting enormous pressure on American drug suppliers to government health programs to buy up Scancell quickly. Scancell has been smart: having got the worldwide rights to exploit the antigens commercially they rushed to get a composition of matter patent for the vaccine and a US patent over its DNA delivery. This has prevented any other company from using the antigens unless they buy Scancell first. I expect a major US company will end up owning Scancell now. There is no way the Americans will relinquish final ownership of their discoveries.
As a footnote to the above: on 11th February 2014 the U. S. Food and Drug Administration (FDA) granted the coveted Orphan Drug Designation to Scancell's SCIB1 ImmunoBody® vaccine for the treatment of metastatic melanoma.
Here's some research and fact checking links:
13th May 2010
Licensing agreement with the U.S. National Institutes of Health.
http://www.scancell.co.uk/Apps/Content/News/?id=186
20th October 2011
Composition of matter patent granted for SCIB1.
http://www.scancell.co.uk/Apps/Content/News/?id=222
9th March 2012
ImmunoBody® vaccine patent approved in the United States.
http://www.scancell.co.uk/Apps/Content/News/?id=244
11th February 2014
SCIB1 Granted FDA Orphan Drug Status.
http://www.scancell.co.uk/Apps/Content/News/?id=313
Its no secret, Scancell's directors plan to sell the British company sometime over the next few years. The Americans are probably the most interested of all in seeing the company cross the Atlantic as Scancell has been given the worldwide rights to use the US Department of Health's melanoma antigens in its lead vaccine, SCIB1. The US government can only get a return on these antigen discoveries when Scancell's vaccine enters the market-place. Scancell has agreed to pay royalties, which the Americans are keen to receive having spent years and millions of dollars developing the antigens at the National Cancer Institute in Bethesda, Maryland.
Here's an intriguing comment by one poster on London South East's Scancell Chat:
Politics! Politics!
The US government owns the melanoma antigens in Scancell's lead vaccine. To get a return on the millions of dollars they have spent developing them, they will be putting enormous pressure on American drug suppliers to government health programs to buy up Scancell quickly. Scancell has been smart: having got the worldwide rights to exploit the antigens commercially they rushed to get a composition of matter patent for the vaccine and a US patent over its DNA delivery. This has prevented any other company from using the antigens unless they buy Scancell first. I expect a major US company will end up owning Scancell now. There is no way the Americans will relinquish final ownership of their discoveries.
As a footnote to the above: on 11th February 2014 the U. S. Food and Drug Administration (FDA) granted the coveted Orphan Drug Designation to Scancell's SCIB1 ImmunoBody® vaccine for the treatment of metastatic melanoma.
Here's some research and fact checking links:
13th May 2010
Licensing agreement with the U.S. National Institutes of Health.
http://www.scancell.co.uk/Apps/Content/News/?id=186
20th October 2011
Composition of matter patent granted for SCIB1.
http://www.scancell.co.uk/Apps/Content/News/?id=222
9th March 2012
ImmunoBody® vaccine patent approved in the United States.
http://www.scancell.co.uk/Apps/Content/News/?id=244
11th February 2014
SCIB1 Granted FDA Orphan Drug Status.
http://www.scancell.co.uk/Apps/Content/News/?id=313
Scancell completes part 1 dosing for cancer study
By Jamie Ashcroft March 21 2014, 8:30am
Cancer drug developer Scancell (LON:SCLP) said it has completed patient dosing in part 1 of its on-going Phase 1/2 clinical trial for the SCIB1 ImmunoBody drug.
Five patients with metastatic tumours were given SCIB1, with doses of 8mg. There were no reported serious adverse events.
Scancell said that immunology and clinical responses are currently being analysed, and will be reported to the market by the end of the second quarter.
Previously patients given lower dosage, 4mg, showed an immune response that might be associated with clinical benefit in patients with malignant melanoma.
Scancell also has permission to expand the second part of the study to include up to 13 patients, receiving 8mg. And with the absence of any serious toxicity in part 1, new patients are being recruited for this stage of the study.
The first patient of the part 2 cohort was dosed with SCIB1 earlier this week.
"Our higher dose 8mg SCIB1 study is progressing well,” said joint chief executive Richard Goodfellow.
“In view of the continued safety profile of SCIB1 at the higher dose, we are now recruiting for Part 2 of this cohort, which will assess the immune and clinical response to SCIB1 in a larger number of patients with Stage III/IV melanoma.
“We look forward to reporting the results from Part 1 of the study later this year."
http://www.proactiveinvestors.co.uk/companies/news/66897/sca…
By Jamie Ashcroft March 21 2014, 8:30am
Cancer drug developer Scancell (LON:SCLP) said it has completed patient dosing in part 1 of its on-going Phase 1/2 clinical trial for the SCIB1 ImmunoBody drug.
Five patients with metastatic tumours were given SCIB1, with doses of 8mg. There were no reported serious adverse events.
Scancell said that immunology and clinical responses are currently being analysed, and will be reported to the market by the end of the second quarter.
Previously patients given lower dosage, 4mg, showed an immune response that might be associated with clinical benefit in patients with malignant melanoma.
Scancell also has permission to expand the second part of the study to include up to 13 patients, receiving 8mg. And with the absence of any serious toxicity in part 1, new patients are being recruited for this stage of the study.
The first patient of the part 2 cohort was dosed with SCIB1 earlier this week.
"Our higher dose 8mg SCIB1 study is progressing well,” said joint chief executive Richard Goodfellow.
“In view of the continued safety profile of SCIB1 at the higher dose, we are now recruiting for Part 2 of this cohort, which will assess the immune and clinical response to SCIB1 in a larger number of patients with Stage III/IV melanoma.
“We look forward to reporting the results from Part 1 of the study later this year."
http://www.proactiveinvestors.co.uk/companies/news/66897/sca…
Scancell: Eine bemerkenswerte Erfolgsgeschichte
http://www.stockhouse.com/companies/bullboard/scnlf/scancell…
http://www.stockhouse.com/companies/bullboard/scnlf/scancell…
Scancell-Aktie auf dem Vormarsch ...... wieder!
Scancell to give AACR presentation on SCIB1 vaccine
Scancell is to present interim data on their SCIB1 vaccine at this month's Annual Meeting of the American Association for Cancer Research (AACR), held in San Diego. The event kicks off tomorrow and runs until April 9th. Scancell will give their presentation on Tuesday, April 8th, between 1:35 PM - 1:50 PM.
AACR is the premier cancer research event with about 18,000 researchers, patient advocates, and other professionals in the cancer field from around the world scheduled to be in attendance. It provides a unique opportunity for members of the worldwide cancer research community to learn about cutting-edge advances, obtain feedback on their own research, and make connections that will foster future collaborations.
Comment by the British blogger Shri9:
"If you follow the industry news on a regular basis you can't fail to read how Scancell''s American competitors enthuse on their websites and in the press that they are to present their trial results at the AACR Annual Meeting. This appears to be a must that so many European and overseas companies get excluded from. Scancell's invitation to present their SCIB1 vaccine's trial results at the AACR ensures a level playing field with regard to the company's promotion in the world's most important oncology market. It is also an important reminder that one of Scancell's most important collaborators on their SCIB1 vaccine is the United States government whose Institutes of Health is to receive royalty payments when the vaccine enters production. Earlier this year the U S Food and Drug Administration (FDA) granted orphan drug designation to SCIB1 qualifying the vaccine for a 50% tax credit for clinical trials, a waiver of the prescription drug user fee for the drug approval procedure and at least seven-year market exclusivity following drug approval by the FDA."
Here is a link to an abstract of the upcoming presentation:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8…
Quelle:
http://www.hotstockmarket.com/t/277760/scnlf-scancell-holdin…
Scancell is to present interim data on their SCIB1 vaccine at this month's Annual Meeting of the American Association for Cancer Research (AACR), held in San Diego. The event kicks off tomorrow and runs until April 9th. Scancell will give their presentation on Tuesday, April 8th, between 1:35 PM - 1:50 PM.
AACR is the premier cancer research event with about 18,000 researchers, patient advocates, and other professionals in the cancer field from around the world scheduled to be in attendance. It provides a unique opportunity for members of the worldwide cancer research community to learn about cutting-edge advances, obtain feedback on their own research, and make connections that will foster future collaborations.
Comment by the British blogger Shri9:
"If you follow the industry news on a regular basis you can't fail to read how Scancell''s American competitors enthuse on their websites and in the press that they are to present their trial results at the AACR Annual Meeting. This appears to be a must that so many European and overseas companies get excluded from. Scancell's invitation to present their SCIB1 vaccine's trial results at the AACR ensures a level playing field with regard to the company's promotion in the world's most important oncology market. It is also an important reminder that one of Scancell's most important collaborators on their SCIB1 vaccine is the United States government whose Institutes of Health is to receive royalty payments when the vaccine enters production. Earlier this year the U S Food and Drug Administration (FDA) granted orphan drug designation to SCIB1 qualifying the vaccine for a 50% tax credit for clinical trials, a waiver of the prescription drug user fee for the drug approval procedure and at least seven-year market exclusivity following drug approval by the FDA."
Here is a link to an abstract of the upcoming presentation:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8…
Quelle:
http://www.hotstockmarket.com/t/277760/scnlf-scancell-holdin…
Wie groß ist der Scancell-Jackpot?
...... sehr groß!
http://www.euroinvestor.com/forum/post-59413-277619-3076229/…
...... sehr groß!
http://www.euroinvestor.com/forum/post-59413-277619-3076229/…
Scancell: Neuer Impfstoff zappt Tumoren
http://www.euroinvestor.dk/debat/post-59413-278359-3088225/s…
http://www.euroinvestor.dk/debat/post-59413-278359-3088225/s…
Zur Information
Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations12 January 2015
Scancell Holdings Plc
Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations 12-15 January, San Francisco
Part 2 patients have median survival time of 28 months since study entry All resected patients are still alive with median survival time of 30 months and 27 months for Stage III and IV patients, respectively
Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces that Joint CEOs Dr Richard Goodfellow and Professor Lindy Durrant will be making corporate presentations 12-15 January 2015, coincident with JP Morgan’s 33rd Annual Healthcare Conference, San Francisco, CA, USA.
A very encouraging update on clinical outcomes in the Company’s on-going Phase 1/2 clinical trial in patients with Stage III/IV melanoma treated with the SCIB1 ImmunoBody® will be given as part of these presentations. It will be reported that the overall median survival of Part 1 patients with tumour present at trial entry and who received at least three doses of 2-8mg of SCIB1 is 24 months. This compares favourably with first line untreated Stage IV disease where patients with no visceral disease had a median survival of 11 months and patients with visceral disease had a median survival of six months (Sosman et al., 2011 Cancer 117:4740-4706). The status of the patients with resected tumours at study entry is equally promising. The 14 patients in Part 2 of the trial have been on study for 23-32 months (median 28 months) and only three have evidence of disease progression. Of particular note, all resected patients (n=16; two from Part 1 and 14 from Part 2) are still alive and only four have progressed. The median recurrence-free survival (when 50% of patients have died) has not been reached; these resected patients have a median survival time of 30 months for Stage III patients (n=9) and 27 months for Stage IV patients (n=7). This compares very favourably with reported data from a peptide vaccine trial following two years of treatment, in which 50% of Stage III patients had disease progression and 19% had died; while 52% of Stage IV patients had disease progression and 33% had died (Slingluff et al., 2011 J Clin Oncol 29:2924-2932).
Richard Goodfellow, Joint CEO of Scancell, said: “The maturing clinical data from our lead ImmunoBody®, SCIB1, continues to enhance our confidence in the clinical value of SCIB1 as monotherapy, especially in the adjuvant setting, a huge and relatively untapped market.”
-ENDS-
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,47 | |
| -0,41 | |
| +0,21 | |
| -0,95 | |
| +0,41 | |
| -0,90 | |
| +0,56 | |
| +0,34 | |
| +1,03 | |
| -2,51 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 198 | ||
| 97 | ||
| 76 | ||
| 74 | ||
| 66 | ||
| 47 | ||
| 46 | ||
| 34 | ||
| 28 | ||
| 27 |
